In this issue of JAMA, Williamson and colleagues1 report the results of a preplanned, appropriately powered subgroup analysis of data from the Systolic Blood Pressure intervention Trial (SPRINT) in persons aged 75 years or older. SPRINT was a randomized, clinical, open-label study of community-dwelling older adults with systolic blood pressure (SBP) in the 130 to 180 mm Hg range in whom the effects of reducing SBP to less than 120 mm Hg (intensive treatment group) were compared with those associated with SBP lowering to less than 140 mm Hg (standard treatment group).2 The primary end point was a composite of cardiovascular disease (CVD) events, including myocardial infarction, acute coronary syndrome, heart failure, stroke, or death from cardiovascular causes. Exclusion criteria included diabetes, history of stroke or heart failure, and SBP less than 110 mm Hg after 1 minute of standing.